The Oncology Report

Re-treatment strategy challenges maintenance therapy for rituximab use in low ...
SAN DIEGO — Patients with low tumor burden follicular lymphoma who received a maintenance dose of rituximab every 3 months did not have a longer time to treatment failure than patients being treated with rituximab at progression, according to findings ...
Observation Suffices After Rituximab in Low-Burden Follicular LymphomaThe Oncology Report
RESORT Study: Rituximab Retreatment Produces Outcomes Comparable to ...Monthly Prescribing Reference

all 5 news articles »